Infections in patients with inflammatory bowel disease receiving anti-tumor necrosis factor agents are not associated with higher serum drug levels

被引：0
|
作者：
Chu, I. E. [1 ,2 ]
Su, H. Y. [1 ,2 ]
Martin, C. [3 ]
Sparrow, M. P. [1 ,2 ]
机构：
[1] Alfred Hosp, Alfred Hlth, Dept Gastroenterol, Melbourne, Vic, Australia
[2] Monash Univ, Melbourne, Vic, Australia
[3] Monash Univ, Sch Publ Hlth & Prevent Med, Dept Epidemiol & Prevent Med, Melbourne, Vic, Australia
来源：
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY | 2018年 / 33卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：89 / 90
页数：2
相关论文
共 50 条
  • [21] Safety of anti-tumor necrosis factor therapy in inflammatory bowel disease
    Frank Hoentjen
    Ad A van Bodegraven
    World Journal of Gastroenterology, 2009, 15 (17) : 2067 - 2073
  • [22] Safety of anti-tumor necrosis factor therapy in inflammatory bowel disease
    Hoentjen, Frank
    Van Bodegraven, Ad A.
    WORLD JOURNAL OF GASTROENTEROLOGY, 2009, 15 (17) : 2067 - 2073
  • [23] Anti-tumor Necrosis Factor Drugs and Risk of Lymphoma in Patients with Inflammatory Bowel Disease
    Blandizzi, C.
    Tuccori, M.
    Ferraro, S.
    Leonardi, L.
    Convertino, I.
    DRUG SAFETY, 2019, 42 (10) : 1245 - 1245
  • [24] Vedolizumab Trough Levels in Children With Anti-Tumor Necrosis Factor Refractory Inflammatory Bowel Disease
    Aardoom, Martine A.
    Jongsma, Maria M. E.
    de Vries, Annick
    Wolthoorn, Jasja
    de Ridder, Lissy
    Escher, Johanna C.
    JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2020, 71 (04): : 501 - 507
  • [25] Therapeutic Drug Monitoring and Safety of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease
    Papamichael, Konstantinos
    Cheifetz, Adam S.
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2021, 19 (04) : 854 - 855
  • [26] ARE ANTI-TUMOR NECROSIS FACTORS ASSOCIATED WITH WEIGHT GAIN IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE?
    Winter, Rachel W.
    Carrellas, Madeline
    Merker, Ami
    Korzenik, Joshua R.
    GASTROENTEROLOGY, 2017, 152 (05) : S410 - S410
  • [27] Listeria monocytogenes infection in patients with inflammatory bowel diseases receiving anti-tumor necrosis factor therapy
    Ramos, J. M.
    Garcia-Sepulcre, M. F.
    Masia, M.
    Brotons, A.
    Grau, M. C.
    Gutierrez, F.
    REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS, 2010, 102 (10) : 614 - U62
  • [28] Anti-tumor necrosis factor a reverts growth hormone resistance associated with inflammatory bowel disease
    Caviglia, R
    Carotti, S
    Gentilucci, UV
    Picardi, A
    Ribolsi, M
    Afeltra, A
    Cicala, M
    GASTROENTEROLOGY, 2005, 128 (04) : A496 - A497
  • [29] LOW RISK OF LYMPHOMA IN PEDIATRIC PATIENTS WITH INFLAMMATORY BOWEL DISEASE TREATED USING ANTI-TUMOR NECROSIS FACTOR AGENTS
    Egberg, Matthew D.
    Smitherman, Andrew
    Zhang, Xian
    Kappelman, Michael
    GASTROENTEROLOGY, 2020, 158 (06) : S968 - S969
  • [30] LOW RISK OF LYMPHOMA IN PEDIATRIC PATIENTS WITH INFLAMMATORY BOWEL DISEASE TREATED USING ANTI-TUMOR NECROSIS FACTOR AGENTS
    Egberg, Matthew
    Smitherman, Andrew
    Zhang, Xian
    Kappelman, Michael
    INFLAMMATORY BOWEL DISEASES, 2020, 26 : S2 - S3
12345